An impurity, probably an anion, present in some batches of the buffer substances 4-(2-hydroxyethyl) piperazine-1-ethanesulfonic acid (HEPES), 2-morpholinoethane sulfonic acid (Mes) and piperazine-l,4-bis(2-ethane sulfonic acid (Pipes), activates the soluble 5'-nucleotidase from rat kidney. The affinity of the enzyme for 5'-IMP and the Vmax were both increased by the unidentified activator. ATP and 2,3-diphosphoglycerate, known activators of the soluble 5'-nucleotidase, had no effect if the incubation media were buffered with batches containing high concentrations of the activating impurity. These results suggest that the impurity interacts with the soluble 5'-nucleotidase at the same site as ATP and 2,3-diphosphoglycerate, however with a much higher affinity than these two compounds. It is possible that the same impurity might interfere with other proteins for which ATP is a substrate or a ligand.

Keywords:
5'-Nucleotidase, ATP, Buffer, 4-(2-Hydroxyethyl) piperazine-1-ethanesulfonic acid, 2-Morpholinoethane sulfonic acid, Piperazine-l,4-bis(2-ethanesulfonicacid), Vanadate
This content is only available via PDF.
1991
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.